These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 34230659)

  • 1. Pembrolizumab use in bladder cancer: a tale of two trials.
    Aragon-Ching JB
    Nat Rev Urol; 2021 Oct; 18(10):577-578. PubMed ID: 34230659
    [No Abstract]   [Full Text] [Related]  

  • 2. NICE's rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
    Gupta S; Kamat AM
    Nat Rev Urol; 2020 Sep; 17(9):491-492. PubMed ID: 32632305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to Pembrolizumab in a Patient With Chemotherapy Refractory Bladder Cancer With Small Cell Variant Histology: A Case Report and Review of the Literature.
    Wilde L; Ali SM; Solomides CC; Ross JS; Trabulsi E; Hoffman-Censits J
    Clin Genitourin Cancer; 2017 Jun; 15(3):e521-e524. PubMed ID: 28143711
    [No Abstract]   [Full Text] [Related]  

  • 4. Pembrolizumab for the treatment of bladder and renal cancer and important new data concerning screening for prostate cancer.
    BJU Int; 2024 Jul; 134(1):4-5. PubMed ID: 38889995
    [No Abstract]   [Full Text] [Related]  

  • 5. A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder.
    Kao C; McNamara M; Alley C; Spector N; Jauhari S; Gupta RT; Zhang T; Zhu J
    Clin Genitourin Cancer; 2019 Jun; 17(3):e672-e677. PubMed ID: 31097390
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA Approves Pembrolizumab for BCG-Unresponsive NMIBC.
    Wright KM
    Oncology (Williston Park); 2020 Feb; 34(2):44. PubMed ID: 32645193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three more immune checkpoint inhibitors for advanced bladder cancer.
    Med Lett Drugs Ther; 2017 Dec; 59(1535):e202-e203. PubMed ID: 29186087
    [No Abstract]   [Full Text] [Related]  

  • 8. Advanced Bladder Cancer Rechallenged With an Immune Checkpoint Inhibitor: A Case Report.
    Bat T; Buck DA; Nathan R; Cinquino J; Sikorski M; Elefante A; Herbst L; Sule N; Fabiano A; George S
    Urology; 2019 Sep; 131():24-26. PubMed ID: 31059726
    [No Abstract]   [Full Text] [Related]  

  • 9. Pembrolizumab Treatment and Pathologic Therapeutic Evaluation for Granulocyte Colony-stimulating Factor-producing Bladder Cancer: A Case Report and Literature Review.
    Muramatsu-Maekawa Y; Taniguchi T; Ito H; Nakane K; Kato T; Tsuchiya T; Miyazaki T; Koie T; Mizutani K
    J Immunother; 2020 May; 43(4):134-138. PubMed ID: 32080020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC.
    Kamat AM; Shore N; Hahn N; Alanee S; Nishiyama H; Shariat S; Nam K; Kapadia E; Frenkl T; Steinberg G
    Future Oncol; 2020 Apr; 16(10):507-516. PubMed ID: 32162533
    [No Abstract]   [Full Text] [Related]  

  • 11. Pembrolizumab for the treatment of bladder cancer.
    Sundahl N; Rottey S; De Maeseneer D; Ost P
    Expert Rev Anticancer Ther; 2018 Feb; 18(2):107-114. PubMed ID: 29284318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic polyradiculoneuropathy associated with pembrolizumab for bladder cancer.
    Kobayashi Y; Iijima K; Kondo Y; Yamamoto K; Sekijima Y
    Acta Neurol Belg; 2024 Jun; 124(3):1063-1065. PubMed ID: 38010574
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer.
    Sarfaty M; Hall PS; Chan KKW; Virik K; Leshno M; Gordon N; Moore A; Neiman V; Rosenbaum E; Goldstein DA
    Eur Urol; 2018 Jul; 74(1):57-62. PubMed ID: 29576265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.
    Necchi A; Raggi D; Gallina A; Madison R; Colecchia M; Lucianò R; Montironi R; Giannatempo P; Farè E; Pederzoli F; Bandini M; Bianchi M; Colombo R; Gandaglia G; Fossati N; Marandino L; Capitanio U; Dehò F; Ali SM; Chung JH; Ross JS; Salonia A; Briganti A; Montorsi F
    Eur Urol; 2020 Apr; 77(4):439-446. PubMed ID: 31708296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Future of Front-line Metastatic Bladder Cancer is Platinum-free.
    Young M
    Eur Urol Focus; 2024 Mar; 10(2):215-216. PubMed ID: 38658299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study.
    Necchi A; Bandini M; Calareso G; Raggi D; Pederzoli F; Farè E; Colecchia M; Marandino L; Bianchi M; Gallina A; Colombo R; Fossati N; Gandaglia G; Capitanio U; Dehò F; Giannatempo P; Lucianò R; Salonia A; Madison R; Ali SM; Chung JH; Ross JS; Briganti A; Montorsi F; De Cobelli F; Messina A
    Eur Urol; 2020 May; 77(5):636-643. PubMed ID: 31882281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A network meta-analysis of the PD(L)-1 inhibitors in the salvage treatment of urothelial bladder cancer.
    Rassy EE; Bakouny Z; Aoun F; Haddad FG; Sleilaty G; Assi T; Kattan J
    Immunotherapy; 2018 Jun; 10(8):657-663. PubMed ID: 29562804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New approval: Avelumab - maintenance therapy for advanced or metastatic urothelial carcinoma].
    Le Brun IC; Benderra MA
    Bull Cancer; 2021 Sep; 108(9):784-786. PubMed ID: 34332742
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.
    Necchi A; Raggi D; Gallina A; Ross JS; Farè E; Giannatempo P; Marandino L; Colecchia M; Lucianò R; Bianchi M; Colombo R; Salonia A; Gandaglia G; Fossati N; Bandini M; Pederzoli F; Capitanio U; Montorsi F; de Jong JJ; Dittamore R; Liu Y; Davicioni E; Boormans JL; Briganti A; Black PC; Gibb EA
    Eur Urol; 2020 Jun; 77(6):701-710. PubMed ID: 32165065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.
    Balar AV; Kamat AM; Kulkarni GS; Uchio EM; Boormans JL; Roumiguié M; Krieger LEM; Singer EA; Bajorin DF; Grivas P; Seo HK; Nishiyama H; Konety BR; Li H; Nam K; Kapadia E; Frenkl T; de Wit R
    Lancet Oncol; 2021 Jul; 22(7):919-930. PubMed ID: 34051177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.